FLNA Stock Forecast: Filana Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Filana Therapeutics, Inc. is $6.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 66 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Filana Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (86): Sales and profits are climbing, and climbing faster than before.
Value (25): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
FLNA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on FLNA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 May 2026 | Maxim Group | Reinstates | Buy | $5.00 |
| 6 Oct 2025 | LUCID CAPITAL MARKETS | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for FLNA.
This page is one stock. Monday covers all of them.
FLNA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
FLNA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Filana Therapeutics, Inc. returned −75.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
FLNA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.6×
- EV / EBITDA
- —
Cheaper than 85% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −60.5%
- Return on assets
- −21.4%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Filana Therapeutics, Inc. has a market value of $32.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$42.3M.
Diluted earnings per share, trailing twelve months: −$0.87.
Free cash flow in the twelve months to 30 June 2026: −$29.3M.
Filana Therapeutics, Inc. employs 17 people.
Data provided by Twelve Data
FLNA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at FLNA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Filana Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about FLNA
What is the FLNA stock price forecast for 2026-2027?
The median 12-month analyst price target for Filana Therapeutics, Inc. is $6.5, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is FLNA stock a buy right now?
Of the 2 analysts covering Filana Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Filana Therapeutics, Inc. 66 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank FLNA?
As at 21 Nov 2026, Filana Therapeutics, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).
Will FLNA stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $6.5, and Ticker Nerd's factor model ranks Filana Therapeutics, Inc. 66 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the FLNA stock forecast for 2030?
No analyst covering Filana Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FLNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.
How has FLNA stock performed over the past year?
Filana Therapeutics, Inc. returned -75.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Filana Therapeutics, Inc. do?
Filana Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing investigational therapies for central nervous system disorders. The company’s current work centers on simufilam, an oral small-molecule candidate being studied for TSC-related epilepsy and other neurological conditions linked to filamin A, along with SavaDx, an early-stage blood-based diagnostic program designed to detect Alzheimer’s disease.
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing investigational therapies for central nervous system disorders. The company’s current work centers on simufilam, an oral small-molecule candidate being studied for TSC-related epilepsy and other neurological conditions linked to filamin A, along with SavaDx, an early-stage blood-based diagnostic program designed to detect Alzheimer’s disease. Based in Austin, Texas, Filana Therapeutics operates in the biotechnology sector with a research-driven model built around drug development and biomarker discovery. Its programs target complex brain disorders where new treatment and diagnostic options remain limited, positioning the company as a specialized participant in the neuroscience and precision-medicine landscape.
CEO Mr. Richard Jon Barry · 17 employees · United States · https://www.filanatx.com